L3VLUP
ProSign in

XBI in the 13F filings

SPDR S&P Biotech ETF · CUSIP 78464A870

Sector · Funds and ETFs
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Dec 2024
the date the book describes
Filed
14 Feb 2025
latest of these filings; the earliest 11 Feb 2025
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q3 2024 and Q4 2024; 3 listed it in both
Shares listed
2,046,141
combined, among listed positions
Reported value
$184m
combined, at the quarter end

Among the 94 comparable managers: 4 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing XBI in Q4 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
Jane Street Group LLC1,315,816$119munder 0.1%Added+371,08814 Feb 2025 (the filing on sec.gov)
Squarepoint Ops LLC592,350$53m0.05%Newnew14 Feb 2025 (the filing on sec.gov)
ExodusPoint Capital Management LP66,917$6.0munder 0.1%Newnew12 Feb 2025 (the filing on sec.gov)
Quantbot Technologies LP48,294$4.3m0.16%Added+11,66311 Feb 2025 (the filing on sec.gov)
Brevan Howard Capital Management LP22,764$2.0munder 0.1%Trimmed-51,75014 Feb 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2024 to Q4 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (2)

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
8 in Q3 2024 to 5 in Q2 2026

Tracked managers listing it, at least.

035810201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
XBI by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20132$5.4mn.a.n.a.
Q3 20132$4.3mn.a.n.a.
Q4 20131$4.4mn.a.n.a.
Q2 20141$3.0mn.a.n.a.
Q1 20152$8.0mn.a.n.a.
Q2 20152$100mn.a.n.a.
Q3 20152$21mn.a.n.a.
Q1 20162$22mn.a.n.a.
Q2 20163$20mn.a.n.a.
Q3 20162$110mn.a.n.a.
Q4 20163$26mn.a.n.a.
Q1 20172$26mn.a.n.a.
Q2 20171$25mn.a.n.a.
Q4 20174$135mn.a.n.a.
Q1 20183$119mn.a.n.a.
Q2 20181$116mn.a.n.a.
Q3 20181$79mn.a.n.a.
Q4 20181$46mn.a.n.a.
Q1 20191$27mn.a.n.a.
Q2 20193$220mn.a.n.a.
Q3 20193$150mn.a.n.a.
Q4 20194$196mn.a.n.a.
Q1 20204$254mn.a.n.a.
Q2 20202$11mn.a.n.a.
Q3 20202$30mn.a.n.a.
Q4 20205$374mn.a.n.a.
Q1 20213$116mn.a.n.a.
Q2 20212$26mn.a.n.a.
Q3 20212$133mn.a.n.a.
Q4 20214$492mn.a.n.a.
Q1 20226$141mn.a.n.a.
Q2 20221$7.3mn.a.n.a.
Q3 20226$268mn.a.n.a.
Q4 20227$588mn.a.n.a.
Q1 202310$509mn.a.n.a.
Q2 20236$229mn.a.n.a.
Q3 20238$204mn.a.n.a.
Q4 20237$392m44
Q1 20248$392m52
Q2 20248$273m63
Q3 20248$272m54
Q4 20245$184m42
Q1 20256$246m51
Q2 20255$173m34
Q3 20252$43m20
Q4 20256$356m810
Q1 20262$178m99
Q2 20265$330m155

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

Choose a stock to compare with XBI →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own XBI, latest filings →Back to the 13F Explorer →